Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evaluating response to metrifonate

P N Tariot1

  • 1Department of Psychiatry, University of Rochester Medical Center, NY 14620, USA.

The Journal of Clinical Psychiatry
|August 28, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knowledge of Risk Factors for Dementia and Attitudes on a Dementia Prevention Program by Age and Ethnicity in Arizona.

JAR life·2024
Same author

Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program.

The journal of prevention of Alzheimer's disease·2023
Same author

The Alzheimer's Prevention Registry: A Large Internet-Based Participant Recruitment Registry to Accelerate Referrals to Alzheimer's-Focused Studies.

The journal of prevention of Alzheimer's disease·2020
Same author

Assessment of Clinical Meaningfulness of Endpoints in the Generation Program by the Insights to Model Alzheimer's Progression in Real Life (iMAP) Study.

The journal of prevention of Alzheimer's disease·2019
Same author

Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred.

The journal of prevention of Alzheimer's disease·2019
Same author

The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial.

The journal of prevention of Alzheimer's disease·2018

Metrifonate, an oral Alzheimer's disease medication, effectively inhibits acetylcholinesterase (AChE) in the brain. Studies show it significantly improves cognition and global function in patients with probable Alzheimer's disease.

Area of Science:

  • Pharmacology and Neurology
  • Neuroscience
  • Geriatric Medicine

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Acetylcholinesterase (AChE) inhibitors are a primary symptomatic treatment for AD.
  • Existing AChE inhibitors may have dose-limiting side effects.

Purpose of the Study:

  • To evaluate the efficacy and safety of metrifonate in patients with probable Alzheimer's disease.
  • To assess metrifonate's pharmacokinetic and pharmacodynamic properties.
  • To compare metrifonate's effects against a placebo.

Main Methods:

  • Oral administration of metrifonate in a once-daily dose.
  • Measurement of brain acetylcholinesterase (AChE) inhibition.
  • Inclusion of preliminary and confirmatory pivotal studies.

Related Experiment Videos

  • Assessment of cognitive function, global function, activities of daily living, and behavior.

    • Main Results:

    • Metrifonate readily enters the brain and inhibits AChE in a dose-dependent manner.
    • Significant cognitive improvement observed in metrifonate-treated patients compared to placebo.
    • Metrifonate demonstrated benefits in global function, encompassing cognition, daily activities, and behavior.
    • The medication is generally well tolerated with a reduced side effect profile.

    Conclusions:

    • Metrifonate is a prodrug converted to a long-acting AChE inhibitor.
    • Metrifonate provides significant symptomatic benefits for patients with probable Alzheimer's disease.
    • Metrifonate is a safe and effective treatment option for Alzheimer's disease symptoms.